In triple-negative breast cancer patients and in vivo mouse models, IL-33 engages eosinophil infiltration into tumors and is essential for the efficiency of cisplatin and anti-PD1 and anti-CTLA4 treatment [74]. This evidence concerns the gene IL33 and triple-negative breast carcinoma.